Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Polycystic Ovary Syndrome 2Leukoplakia, Oral 2Thyroid Cancers That Contain the PAX8-PPARgamma Fusion Gene 1Skin Neoplasms 1Pancreatic Neoplasms 1Lung Neoplasms 1Liposarcoma, Myxoid 1Liposarcoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Head and Neck Neoplasms 1Carotid Intimal Medial Thickness 1 1Carcinoma, Squamous Cell 1Breast Neoplasms 1

Interventions

Metformin 3Pioglitazone 2Specimen Handling 1Rosiglitazone 1Photochemotherapy 1Nivolumab 1Dihematoporphyrin Ether 1Celecoxib 1Biopsy 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Leukoplakia, Oral × Pioglitazone × Clear all
NCT00099021 2022-02-11

Pioglitazone Hydrochloride in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia

National Cancer Institute (NCI)

Phase 2 Completed
21 enrolled 6 charts
Head & Neck

Head and Neck Neoplasms, Leukoplakia, Oral

NCT00951379 2016-04-06

Pioglitazone for Oral Premalignant Lesions

National Cancer Institute (NCI)

Phase 2 Terminated
52 enrolled 23 charts
Head & Neck

Leukoplakia, Oral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡